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The hippocampal region of rats and mice after a single
intraperitoneal dose of clioquinol: loss of synaptic zinc, cell
death and c-Fos induction
Abstract
Clioquinol (CQ) is able to chelate synaptic zinc, which can modulate excitatory and inhibitory
neurotransmission. In humans, CQ was associated with cases of transient global amnesia (TGA) and
with the neurodegenerative syndrome subacute myelo-optico-neuropathy (SMON). We examined the
CQ induced loss of synaptic zinc, cell death and c-Fos induction in rats and mice. In rats, we found a
strong reduction of histochemically reactive synaptic zinc no later than four hours after the injection of
the lowest dose of CQ (50 mg/kg) and, for all doses used, a return to control levels after 48 hours. There
was no evidence of cell death for any dose and up to one week after CQ injections. Only a slight
induction of c-Fos was seen in the hippocampus for the higher doses used (100-200 mg/kg). In mice
injected with 100 mg/kg, CQ also resulted in a fast loss of synaptic zinc. c-Fos was induced after 4
hours in cell populations of the hippocampal region and other parts of the telencephalon, and
substantially increased after 24 hours. One day after the injection we found a pattern of cell loss (hilus,
parts of CA3, CA1 and layer III of the medial entorhinal cortex) reminiscent of that seen in models of
temporal lobe epilepsy. In conjunction with published data on the behavioral effects of zinc chelation
and the modulatory effects of zinc in excitatory neurotransmission, our results indicate that the loss of
synaptic zinc may have been involved in TGA and the neuropathology associated with SMON.
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CQ, Clioquinol; SMON, subacute myelo-optio-neuropathy; LTP, long term potentiation; 
TGA, transient global amnesia 
 
 3
ABSTRACT 
Clioquinol (CQ) is able to chelate synaptic zinc, which can modulate excitatory and inhibitory 
neurotransmission. In humans, CQ was associated with cases of transient global amnesia 
(TGA) and with the neurodegenerative syndrome subacute myelo-optico-neuropathy 
(SMON). We examined the CQ induced loss of synaptic zinc, cell death and c-Fos induction 
in rats and mice. In rats, we found a strong reduction of histochemically reactive synaptic zinc 
no later than four hours after the injection of the lowest dose of CQ (50 mg/kg) and, for all 
doses used, a return to control levels after 48 hours. There was no evidence of cell death for 
any dose and up to one week after CQ injections. Only a slight induction of c-Fos was seen in 
the hippocampus for the higher doses used (100-200 mg/kg). In mice injected with 100 
mg/kg, CQ also resulted in a fast loss of synaptic zinc. c-Fos was induced after 4 hours in cell 
populations of the hippocampal region and other parts of the telencephalon, and substantially 
increased after 24 hours. One day after the injection we found a pattern of cell loss (hilus, 
parts of CA3, CA1 and layer III of the medial entorhinal cortex) reminiscent of that seen in 
models of temporal lobe epilepsy. In conjunction with published data on the behavioral 
effects of zinc chelation and the modulatory effects of zinc in excitatory neurotransmission, 
our results indicate that the loss of synaptic zinc may have been involved in TGA and the 
neuropathology associated with SMON. 
 
KEYWORDS 
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amnesia, temporal lobe epilepsy 
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Clioquinol (5-chloro-7-iodo-8-hydroxyquinoline; CQ) was a component in medicines 
to treat for example traveller’s diarrhoea and other bowel symptoms.  CQ acts as a chelator, 
which forms lipophilic chelates with cations like zinc, iron or nickel. In the 1960s, CQ was 
linked to subacute myelo-optic-neuropathy (SMON) in Japan (Kono, 1971). SMON 
symptoms included sensory disturbances, motor paralysis and loss of visual acuity, which 
correlated with axonal damage and demyelination of the optic nerve, lateral and posterior 
columns of the spinal cord and peripheral nerves. With the prohibition of CQ-containing 
medicines in 1970, the number of SMON cases in Japan decreased dramatically (Kono, 1975; 
Egashira and Matsuyama, 1982). 
In addition to SMON, cases of acute encephalopathy similar to classic transient global 
amnesia (TGA) have been described after the intake of large doses of CQ. The CQ-type of 
TGA is characterised by an insidious start in cases mostly younger than those affected by the 
classic type. Patients were not able to retain what was shown or said to them, while they were 
otherwise able to act apparently normally and even to execute complex activities. During the 
acute amnesic episode, which could last up to 3 days (longer than in the classic type), there 
was also a retrograde amnesia, which could extend over months or years. After the episode of 
TGA, the capability to retain impressions returned and the retrograde amnesic gap was filled 
again. In both the classic and the CQ-type only the acute episode remained ‘blank’ (Ferrier 
and Eadie, 1973; Mumenthaler et al., 1979; Kaeser, 1984) 
Although CQ was clearly the cause of the reported cases of TGA and almost 
conclusively established as the cause of SMON, a clear mechanistic link between cause and 
effect was never established. Waning interest in such a link after the virtual disappearance of 
SMON may in part be attributed to the fact that zinc only established itself in the arena of 
endogenous neuromodulators in the 1980s. Zinc is a potent modulator of excitatory 
neurotransmission effecting both NMDA and non-NMDA glutamate receptors (Harrison and 
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Gibbons, 1994; Smart et al., 1994) through interactions with subunit specific zinc-binding 
sites (Kawajiri and Dingledine, 1993; Zheng et al., 1994; Paoletti et al., 2000; Choi et al., 
2001; Rachline et al., 2005). While telencephalic GABAergic cells do not seem to use zinc as 
a neuromodulator (Pérez-Clausell and Danscher, 1985; Slomianka et al., 1997), effects of zinc 
on GABAergic transmission are robust and specific in vitro (Smart et al., 1994; Wang et al., 
1995; Wooltorton et al., 1997; Hosie et al., 2003). Interactions of zinc released from 
excitatory boutons with GABAergic transmission or a colocalization of zinc and GABA 
outside the telencephalon seem possible (Birinyi et al., 2001; Wang et al., 2001). In addition 
to glutamatergic and GABAergic transmission, zinc has been found to modulate the function 
of receptors of most other major neurotransmitters in vitro. Recent evidence for a 
colocalization of zinc and glycine in the spinal cord (Birinyi et al., 2001) also support an in 
vivo role (Hirzel et al., 2006) of the modulation of glycinergic transmission by zinc (Laube et 
al., 1995; Miller et al., 2005). 
Initially we became interested in the administration of CQ in animals that could serve 
as negative controls in histochemical studies of zinc-containing pathways (Slomianka et al., 
1990) as large single doses (up to 400 mg/kg) of CQ did not show overt toxicity in rats 
(Kotaki et al., 1983). However, our first observations in mice and early literature on 
experimental findings in mice, dogs and cats, describing overt tonic-clonic seizures or 
seizure-like behaviors and associated histopathology in the hippocampus (Püschner and 
Fankhauser, 1969; Tateishi et al., 1973; Lannek and Jonsson, 1974; Krinke et al., 1978), 
prompted a more thorough reassessment of the effects of CQ in mice and rats. Effects of CQ 
may not only help to refine ideas on the function of zinc in the normal CNS, but are also of 
clinical interest. First, there are two case reports of acute seizures after CQ administration 
(Ogawa et al., 1975 as cited by Mumenthaler et al., 1979; Fisher et al., 1993) and two CQ-
induced TGA patients — the only ones for whom a follow up is found in the literature — 
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presented with temporal lobe epilepsy of unknown origin several years after the TGA episode 
(Ferrier et al., 1987). Second, interest in CQ and CQ-like compounds has re-emerged as a 
possible treatment for Alzheimer’s disease. Amyloid β protein (Aβ) has binding sites for zinc 
(Bush et al., 1993), and the addition of zinc promotes the formation of insoluble Aβ deposits 
(Mantyh et al., 1993; Bush et al., 1994; Essler et al., 1996). Administration of CQ seems to be 
able to solubilize Aβ deposits in transgenic models of Alzheimer’s disease (Cherny et al., 
2001), and clinical trials were initiated to test for possible beneficial effects of CQ in 
Alzheimer’s disease patients (Regland et al., 2001; Bush, 2002; Ritchie et al., 2003).  
Here we report (1) the effect of intraperitoneally administered (i.p.) CQ on the 
distribution of zinc in the CNS of rats and mice at doses spanning the range from those that 
are likely to result in CQ-induced TGA in humans to doses that exceed those necessary to 
induce massive cell loss and seizures in mice, (2) histopathological changes associated with 
i.p. CQ administration in mice and (3) i.p. CQ-induced expression of the immediate early 
gene protein c-Fos as a marker for CQ-induced changes of neuronal function. 
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EXPERIMENTAL PROCEDURES 
 
Animals 
We used Wistar-Kyoto and Sprague-Dawley male and female rats, weighing from 82 
to 232 grams, and male DBA mice, weighing from 27 to 31 grams. 
The animals were fed ad libitum and maintained under standard laboratory conditions 
of 24°C and 12-12 h light-dark cycle. All animal experiments reported here were approved by 
the Animal Ethics and Experimentation Committee (AEEC) of the University of Western 
Australia. 
 
Clioquinol administration 
CQ was stirred thoroughly into Castor oil (50 mg CQ/ml) until the suspension had a 
homogeneous, ‘lotion-like’ appearance. Suspensions were kept refrigerated and not used for 
more than 2 to 3 days. Rats were injected intraperitoneally with 50, 100 or 200 mg/kg CQ. 
Control animals were either injected with Castor oil only (n=11) or left without treatment 
(n=4). 
15 mice were injected intraperitoneally with 100 mg/kg CQ. Eleven mice were used as 
controls (Castor oil only, n=7; no treatment, n=4). 
For animal numbers and survival times following CQ injections see Table 1. 
Tissue processing 
To demonstrate zinc using Timm's sulphide silver method (Danscher, 1981; Geneser et 
al., 1993), animals were deeply anaesthetized with sodium pentobarbital and perfused 
transcardially with 0.5% sodium sulphide in 0.15 M phosphate buffer (SPB; pH 7.4) for two 
minutes at a pressure of ~120 mmHg prior to 4% PFA in 0.15 M phosphate buffer (pH 7.4) at 
room temperature for 6-8 minutes. To demonstrate vesicular zinc using the selenium method, 
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20 mg/kg Na2SeO3 in H2O (1ml/100g) was injected i.p. under a light ether anesthesia one 
hour prior to pentobarbital anesthesia and perfusion with 4% PFA. 
Brains were postfixed for 2 hours, cryoprotected in 30% sucrose and frozen. Serial 40 
μm sections were cut and either mounted on slides or collected into a cryoprotectant to be 
stored at -30°C until further processing. 
Slides were immersed in a developer (Danscher, 1981; Geneser et al., 1993) made 
from 60 ml of protective colloid (50% w/v gum arabic in deionized water) and 10 ml citrate 
buffer (25.5 g citric acid × H2O and 23.5 g sodium citrate × 2H2O dissolved in deionized 
water to a total volume of 100 ml). Freshly prepared solutions of 0.85 g hydroquinone in 15 
ml deionized H2O and 0.12 g silver lactate dissolved in 15 ml deionized H2O were stirred into 
the developer immediately before use. Sections were developed at 26°C in the dark for 60 to 
70 minutes. 
To demonstrate c-Fos, free-floating sections were rinsed, incubated for one hour in 1% 
triton in Tris-buffered saline (pH 7.4; TBS; 0.9 % NaCl), rinsed and incubated for 1 hour in 
TBS containing 4% normal goat serum (NGS) and 2.5 mg/ml bovine serum albumin. After 
additional rinses, sections were incubated for 24 hours at room temperature in primary rabbit 
c-Fos antibody (PC38; Oncogene, Cambridge, MA) at a dilution of 1/40000 in TBS with 1% 
NGS. Thereafter, sections were rinsed and incubated in secondary biotinylated goat anti-
rabbit antibodies (Vectastain Elite ABC kit, Vector Laboratories, Burlingame, CA) at 1/200 in 
TBS and 1% NGS for 1 hour. Finally, sections were again rinsed, incubated in avidin-biotin 
complex for 20 minutes and stained using diaminobenzidine as chromogen. Omission of the 
primary antibody from the incubation solutions abolished immunoreactivity with the 
exception of a faint, homogeneous background stain. 
One series from each animal was Nissl stained using acidic toluidine blue. 
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Digital microphotographs were adjusted in brightness and contrast to resemble the 
appearance of the sections under the microscope and grey-scaled. No local changes were 
made in the images. 
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RESULTS 
 
Histochemical staining for vesicular zinc 
Mice. Staining intensity decreased dramatically within four hours after the injection of 
100 mg/kg CQ (Fig. 1 a, b). In a few animals, we did not observe any residual staining for 
vesicular zinc (Fig. 1b). More commonly, the staining pattern resembled that also seen in rats 
(Fig. 1 e,g): low levels of staining were still observed in the dentate hilus, hippocampal mossy 
fibres and in superficial layers of extra-hippocampal cortical areas. Twenty-four hours after 
the CQ injections, we did not observe clear differences between experimental and control 
animals (Fig. 1c). 
 
Rats. Similar to mice, four hours after the injection of 50-200 mg/kg CQ in vehicle, a 
dramatic decrease in staining intensity was observed throughout the brain (Fig. 1 d-g). In most 
animals, histochemically reactive zinc disappeared, with the exception of a very light residual 
staining in mossy fibres and, occasionally, superficial stratum radiatum of CA3 and 
superficial cortical layers. We did not observe clear regional differences in response to a given 
dose or differences within a region that may be related to the dose. A complete lack of 
staining was only observed in one animal. We did not observe differences in the effect of a 
100 mg/kg dose between Wistar-Kyoto rats and Sprague-Dawley rats. Forty-eight hours after 
the CQ injection we did not observe clear differences between experimental and control 
animals. 
In rats injected with the highest doses and after the shortest survival times, small 
amounts of the injected volume were still found in the peritoneal cavity at the time of 
perfusion. 
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c-Fos induction 
Mice. Control mice, which were injected with sodium selenite, appeared similar to 
animals injected only with vehicle only for all survival periods tested. c-Fos was 
constitutively expressed in the nuclei of a small number of cells in the hilus, the pyramidal 
cell layer of CA1 and CA3, the proximal subiculum, layer III of the entorhinal cortex and, 
outside the hippocampal region, in, e.g., the perirhinal, temporal and piriform cortex (Fig. 2 
a,d,g,j). 
Four hours after the injection of 100 mg/kg CQ, a large number of small nuclei in the 
hilus were c-Fos positive (c-Fos+). Most of them were found in the subgranular zone (Fig. 
2e). There was also a clear increase in the number of c-Fos+ granule cells, but they still 
accounted for only a small fraction of all granule cells. c-Fos+ cells were also seen in the 
pyramidal cell layer, especially in proximal CA3 (Fig. 2e), but overall the induction was less 
pronounced than in the dentate gyrus. c-Fos+ cells were rare or absent at the transition from 
CA3 to CA1. In the entorhinal cortex, especially in layer III, the number of c-Fos+ cells 
increased slightly. A moderate increase of of c-Fos+ cells was seen in the presubiculum and 
lateral septal nuclei, and very high numbers were found in the perirhinal (Fig. 2b) and 
piriform cortex. Increases in the number of c-Fos+ cells were also found in the temporal (Fig. 
2l) and frontal cortices. 
Twenty-four hours after the injection of 100mg/kg CQ, c-Fos induction was variable 
in granule cell layer, often involving cells positioned superficially in the granule cell layer 
(Fig. 2f), which showed moderately c-Fos+ nuclei. In one animal, in which we did not 
observe c-Fos in this layer, induction was also minimal in CA1 and CA3 (see below). In the 
hilus, both the number and staining intensity of c-Fos+ large, round hilar nuclei increased 
dramatically (Fig. 2f) in animals in which cells with a neuronal morphology were still present 
in Nissl-stained sections (see section on cell death). 
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CA1 and CA3 contained c-Fos+ cells in all layers. Staining in the pyramidal cell layer 
appeared proportional to the number of cell with a neuronal morphology remaining in the 
layer in Nissl-stained sections. In mice in which extensive degenerative changes were seen in 
the pyramidal cell layer, a large number of small, pleiomorphic c-Fos+ nuclei were observed 
throughout the layers of the hippocampus (Fig. 2i). When the pyramidal cells appeared largely 
unaffected, c-Fos+ pyramidal cell nuclei were the dominant immunoreactive structures in 
CA1 (Fig. 2j) and CA3. All cells appeared c-Fos+ in the pyramidal cell layer of two out of 
four animals, with the exception of the transition from CA3 to CA1 in which c-Fos+ cells 
were seen in only one animal.  
Induction was variable also in the presubiculum and entorhinal cortex, ranging from 
animals without an apparent induction of c-Fos to animals with very large numbers of c-Fos+ 
cells. Outside the hippocampal region, marked increases in the number of c-Fos+ cells were 
seen throughout the cortex, which were most pronounced in the piriform, perirhinal, temporal 
(Fig. 2m) and frontal cortices. In general, increases paralleled the changes observed in the 
hippocampal region — in animals in which the hippocampus was strongly affected, most if 
not all cells were c-Fos+ in the later regions. 
 
Rats. There was no apparent difference in distribution and appearance of 
immunoreactive cells between control rats injected with castor oil vehicle (Fig. 3a) and 
untreated control rats. Three to five hours after CQ injection, there was a substantial increase 
in the number of immunoreactive cells in the dentate gyrus of rats injected with 100 or 200 
mg/kg CQ (Fig. 3b). Most c-Fos+ nuclei induced by CQ appeared small and pleiomorphic, 
while the number of large, round c-Fos+ nuclei was only modestly increased. A band of c-
Fos+ cells was seen in the subgranular zone immediately beneath the granule cell layer (Fig. 
3c). Their morphology and distribution resembled cells found in the subgranular zone of mice 
four to 24 hours after the CQ injection (Fig. 2e,f). One animal also showed slightly increased 
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staining in the CA1 pyramidal cell layer and subiculum, while another animal did not show a 
noticeable induction of c-Fos in any area. We did not observe an induction of c-Fos in animals 
allowed to survive for nine hours to one week after the injection of CQ. 
 
Cell death 
Mice. We did not observe signs of cell death in control mice (Fig. 4a) or in mice 
injected with CQ up to 4.5 hours prior to sacrifice. Twenty-four hours after CQ 
administration, cell death was observed in the granule cell layer of three out of ten animals 
(Fig. 4b). Evidence of cell death was always visible in the hilus (Fig. 4b,c) and correlated with 
the involvement of the granule cell layer. In the three animals in which the granule cell layer 
was affected, the hilus was essentially devoid of cells of a neuronal phenotype (Fig. 4b). In 
the remaining animals the loss of cells was more restricted. It often occurred in the form of 
small, selectively affected areas devoid of neurons (Fig. 4c), whichas neighbouring hilar areas 
in the same section did not show such an effect. In all experimental animals, small, dark, 
pleiomorphic nuclei remained visible even though cells of a neuronal phenotype had 
vanished. Such nuclei, which were never observed in control animals (Fig. 4d), were also 
found in experimental animals with no apparent decrease in the density of neurons (Fig. 4e). 
In CA3, the proximal segment of the pyramidal cell layer was affected in all animals 
in which cell death was apparent in the hilus (Fig. 4b,c). The affected zone corresponded well 
to that in which a c-Fos induction was apparent (Fig. 2e,f). Septally, the affected zone 
extended towards CA1 in animals with extensive hilar damage. Cells, which were apparently 
not affected, were in these cases only found in a small segment of the pyramidal cell layer at 
the border between CA3 and CA1 (Fig. 4f). 
Histopathological signs in CA1 were variable. In two mice, CA1 was indistinguishable 
from that in control animals (Fig. 4g). In the remaining animals, evidence of cell death ranged 
from the appearance of small, round and darker nuclei with multiple fine chromatin 
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condensations scattered among normal appearing CA1 pyramidal cells (Fig. 4h) to the almost 
complete replacement of the pyramidal cell layer by such nuclei (Fig. 4i). 
In five out of ten mice the subiculum showed signs of cell death, especially in the 
proximal part. In four out of ten animals, affected cells were also found in the presubiculum. 
In six out of ten animals, the entorhinal area was affected. Layers III and VI seemed to 
be the most sensitive — in particular in the medial entorhinal cortex. Notably, layer III was 
strongly affected in animals in which there seemed to be little damage to CA1 (Fig. 4k). In 
these animals, small dark nuclei seemed to replace most cells with a neuronal phenotype (Fig. 
4l). In contrast, layer III was spared in animals in which cell damage was extensive in CA1 
(Fig. 4m). 
Outside the hippocampal region cell death was apparent in the piriform cortex.  
 
Rats. At no time point did we observe cell death or other histopathological signs in the 
areas in which c-Fos was induced or in areas in which cell death and/or c-Fos induction were 
prominent in mice (Fig. 5). 
 
Behavior 
 Home cage observation of rats showed a moderate behavioural suppression in the 
period from approximately two to eight hours after the administration of 200 mg/kg CQ. 
Thereafter, no overt behavioural differences between control and experimental animals were 
noted at the time of perfusion. Lower doses did not have noticeable behavioural effects.  
Mice showed a behavioural suppression, bristled fur and fixed gaze ('staring') within 90 
minutes of the CQ administration, which for some animals persisted until 24 hours. Most 
animals showed a subsequent phase of hyperactivity and circling behaviour, which also could 
be elicited by an auditory stimulus in animals, which appeared behaviourally depressed. Some 
animals progressed to a stage of "popcorn-bouncing" activity. The onset of the later stage was 
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variable, but occurred as early as four hours after CQ administration in one animal. The 
behavioral sequelae correspond closely to the development of kainite-induced seizures in C3H 
mice described by McKhann et al (McKhann et al., 2003).  
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DISCUSSION 
 
CQ-related loss of synaptic zinc, TGA and SMON 
We show that a single low dose of CQ results in the quick loss of histochemically 
stainable, vesicular zinc, which reappears no later than 24 (mice) or 48 hours (rats) thereafter. 
Possible effects of CQ on other, histochemically 'silent', pools of cations can not be excluded, 
but, as will be discussed, are not necessary to explain CQ effects. 
Vesicular zinc is involved in the modulation of LTP (Lu et al., 2000; Kodirov et al., 
2006), one of the cellular mechanism mediating learning and the formation of memories, and 
the chelation of zinc impairs learning in behavioural tasks (Frederickson et al., 1990; Lassalle 
et al., 2000; Daumas et al., 2004). A CQ-related change of hippocampal physiology may be 
sufficient to explain the short term amnesic symptoms of acute CQ-encephalopathy (Ferrier 
and Eadie, 1973; Mumenthaler et al., 1979; Kaeser, 1984). The time course of the loss of zinc 
after CQ administration is however somewhat faster than that of CQ-TGA. It is possible that 
the loss of vesicular zinc is more protracted in humans, but even if that should not be the case, 
hippocampal function may take longer to return to normal. Also, the functional consequences 
of alterations in hippocampal gene transcription indicated by the induction of c-Fos may 
outlast the initial effects of the loss of vesicular zinc. 
In contrast to CQ-TGA, the pathogenesis of SMON is dominated by visual and motor 
impairments but not - at least initially - by overt cognitive dysfunction. In laboratory animals, 
the repeated daily administrations of 100-400 mg/kg CQ in rats led to ataxia of the legs 
(Kotaki et al., 1983). However, degenerative changes in the long fibre tracts of the spinal 
cord, which is a characteristic finding in SMON (Kono, 1975), were not observed. In dogs, 
CQ administration resulted in disturbances of visual acuity and of motor function of the hind 
legs. The pathological findings, symmetrical destruction of the long tracts in the spinal cords, 
such as posterior and lateral tracts, especially of the fasciculus gracilis (Goll’s tract) in the 
 17
upper cervical cord, degeneration of the spinal nerve rootlets, peripheral nerves and the spinal 
root ganglia, demyelination of the optic nerves and tracts (Tateishi et al., 1973), were quite 
similar to human SMON cases (Shiraki, 1971). Oligodendrocytes do express receptors types 
(Gallo and Ghiani, 2000; Káradóttir et al., 2005) that are sensitive to zinc. The activation of 
kainate receptors sensitizes oligodendrocytes to excitotoxic injury and complement attack 
(Alberdi et al., 2002; Alberdi et al., 2006). Recent work also shows that glutamate is released 
in white matter (Kukley et al., 2007; Ziskin et al., 2007). Oligodendrocyte death has been 
observed in the optic nerve after AMPA- or kainate-receptor or glutamate tranporter 
inhibition (Sánchez-Gómez et al., 2003; Domercq et al., 2005). These observations provide a 
mechanistic framework in which a CQ-induced loss of zinc could elicit white matter damage. 
CQ doses reported for SMON patients typically range around 1.5 g/day (Egashira and 
Matsuyama, 1982) taken over prolonged periods of time. Doses overlap with those that have 
been reported for CQ-TGA, which range from 1.2 g to a total of 10 g/day (Mumenthaler et al., 
1979).  In humans, the intake of 0.75 and 1.5 g CQ results in peak plasma levels of 10 and 20-
30 μg/ml after four hours (Jack and Riess, 1973), which corresponds closely to those observed 
in rats after a single CQ dose of 100 or 200 mg/kg — ~10 and 20 μg/ml respectively (Kotaki 
et al., 1983). Doses applied in our study should fall within the range that produce blood 
plasma levels in humans associated with CQ-TGA and SMON. Notably, a loss of synaptic 
zinc has been observed in CD1 mice two hours after the administrations of as little as 30 
mg/kg CQ i.p. (Nitzan et al., 2003) — longer-term functional and histopathological effects 
were not investigated. 
 
CQ-related histopathology 
There is a clear resemblance of CQ- and TLE-related cell death in humans and in 
animal models of TLE. Hilar neurons are very sensitive to seizures (Margerison and Corsellis, 
1966; Cavazos and Sutula, 1990; Scharfman and Schwartzkroin, 1990) and are invariably 
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affected in mice after CQ-administration. Similar to the effect seen after CQ, proximal CA3 is 
commonly involved in seizure-associated end folium sclerosis and, when CA1 and distal parts 
of CA3 become involved (Sommer, 1880; Margerison and Corsellis, 1966), a small segment 
between them, commonly identified as CA2, is often spared (Leranth and Ribak, 1991; 
Sloviter et al., 1991). A loss of cells in layer III of the entorhinal cortex is also observed in 
TLE and TLE-models (Du et al., 1993; Du et al., 1995; Eid et al., 1995). Notably, after CQ 
administration, this effect was only clear when the impact of CQ on CA1 was limited. 
Presubicular lesions ameliorate entorhinal damage after kainate-induced seizures (Eid et al., 
2001), and presubicular afferents of the entorhinal cortex terminate preferentially in a field 
corresponding to the area affected after CQ (Köhler, 1985; Caballero-Bleda and Witter, 1993; 
Eid et al., 1996). CA1 has only limited connections to the presubiculum or layer III of the 
entorhinal cortex (Swanson and Cowan, 1977; van Groen and Wyss, 1990) leaving it an open 
question if and how CQ-induced entorhinal damage is mediated by CA1. 
Protective as well as proconvulsive roles have been suggested for zinc in the 
development of seizures and seizure-related pathology. The removal of zinc either in culture 
media in in vitro experiments or by chelation in vivo may elicit seizures or seizure-like 
activity or is, at least, pro-convulsive (Mitchell et al., 1990; Mitchell and Barnes, 1993; 
Blasco-Ibáñez et al., 2004; Domínguez et al., 2006). Zinc chelation results in neuronal death 
after kainate doses that do not elicit seizures or cell death by themselves (Domínguez et al., 
2003). Also, an increased seizure sensitivity has been observed in AP-3 null mutant (mocha-) 
mice, which also show decreased levels of synaptic zinc and zinc-transporter-3 (Zn-T3)  
(Kantheti et al., 1998), and in Zn-T3 knockout mice (Cole et al., 2000; Lopantsev et al., 
2003). Both protective and pathology promoting effects of zinc, depending on timing and 
dose, were noted by Nave and Connor (1993). These findings contrast with the induction of 
seizures or sensitisation towards seizure-inducing agents by zinc and the idea of a 
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translocation of synaptic zinc to postsynaptic neurons as a mechanism of seizure-induced cell 
death (Frederickson et al., 1989; Shiraishi et al., 1993; Suh et al., 2001)  
Although zinc-containing aberrant mossy fibres, which are formed in the course of 
TLE and in seizure models (Tauck and Nadler, 1985; Sutula et al., 1988; Babb et al., 1991), 
have been suggested to alter GABAergic transmission in a pro-convulsive manner (Buhl et 
al., 1996; Cohen et al., 2003), this mechanism may not be operative in vivo (Wright, 1986; 
Molnár and Nadler, 2001). Interestingly, zinc also accumulates in dying neurons after the 
induction of seizures in Zn-T3 knockout mice (Lee et al., 2000) which lack synaptic zinc. 
Intracellular metallothionein-III was suggested as an alternative source of zinc (Lee et al., 
2003).  A recent report (Lavoie et al., 2006), which relates pathology-promoting effects of 
zinc to intracellular stores of effected cells, suggests that the differential roles of zinc in the 
development of seizures may be played by different pools of this metal, which may reconcile 
most discrepant observations. A speculative link between the two pools may be the inhibition 
of nitric oxide synthase by synaptic (?) zinc (Abou-Mohamed et al., 1998; Perry and Marletta, 
1998) and the liberation of zinc from metallothioneins by nitric oxide (Cuajungco and Lees, 
1998; Aravindakumar et al., 1999; Binet et al., 2002). A nitric oxide-mediated release of zinc 
from intracellular neuronal stores has been observed (Cuajungco and Lees, 1998), including 
cell populations that are only sparsely innervated by zinc-containing boutons (Frederickson et 
al., 2002), leading to cell death in vitro (Bossy-Wetzel et al., 2004; Zhang et al., 2004). 
Alternatively, the effects of zinc may follow the 'too much or not enough' pattern common to 
many bioactive substances. 
 Unfortunately, we have not been able to unequivocally identify the cells that show the 
earliest c-Fos response to CQ in mice and the virtually only response found in rats. The 
morphology of the c-Fos+ nuclei, small and pleiomorphic, in conjunctions with the absence of 
neuronal damage or clear neuronal c-Fos induction in rats suggests that these are glial cells. 
After the repeated administration of CQ also rats will develop seizures (Kotaki et al., 1983). 
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In the context of a possible involvement of astrocytes in the development of seizures (Babb et 
al., 1997; Kang et al., 2005; Tian et al., 2005) it is interesting that glial cells may be the first 
cells to respond to this 'CQ-kindling'. In view of the results obtained by us and others it is not 
surprising that TLE is among the possible long-term outcomes of CQ-intoxication (Ferrier et 
al., 1987) and, although not concerning TLE, a kindling-like effect may have been observed 
by Mumenthaler et al. in one CQ-TGA case in which a second, lower therapeutic dose of CQ 
caused a second episode of CQ-TGA (Mumenthaler et al., 1979). 
 
Species, strain and inter-individual differences in CQ effects 
In contrast to mice, we did not find any sign of neuronal death in sensitive regions of 
the hippocampus or in other regions examined in rats. This observation is compatible with 
previous findings suggesting strain and species differences in the sensitivity to CQ toxicity 
related to differences in CQ metabolism (Tateishi et al., 1973; Kotaki et al., 1986). Inter-
individual differences observed in the severity of CQ effects observed here may result from 
individually different CQ-absorption, peak plasma CQ levels and/or CQ-clearance. These 
parameters have been described to vary both in laboratory animals (Kotaki et al., 1983; 
Kotaki et al., 1986) and in humans (Jack and Riess, 1973; Mumenthaler et al., 1979). Inter-
individual differences have allowed the establishment of CQ-sensitive/resistant substrains 
(Kotaki et al., 1986). 
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FIGURE LEGENDS 
 
Figure 1 
(a-c) Hippocampal region  and retrohippocampal cortices of DBA mice stained for vesicular 
zinc using the selenium method, scalebars:  500 μm. (a) control, (b) 4 hours after 100 mg/kg 
CQ in castor oil vehicle i.p.. Although the complete absence of histochemically reactive zinc 
illustrated here was common in mice, the majority of the animals showed a residual staining 
in the hilus and mossy fiber zone similar to that seen in rats. (c) 24 hours after 100 mg/kg CQ 
i.p. 
(d-g) Timm (sulphide silver) stained hippocampal region of rats, scalebars: 500 μm. (d) 
control Wistar-Kyoto rat, (e) Wistar-Kyoto rat 4 hours after 50 mg/kg CQ i.p. Residual 
staining for histochemically reactive zinc is seen in the hilus, mossy fiber zone and stratum 
radiatum of CA3. (f) control Sprague-Dawley rat. (g) Sprague-Dawley rat 4 hours after 100 
mg/kg CQ i.p. Some residual staining for zinc is seen in the hilus and dentate gyrus molecular 
layer. Vascular staining visible in d-g often occurs in PFA fixed Timm-stained sections, but is 
absent when the selenium method (a-c) is used. 
 
Figure 2 
Mouse, c-Fos immunoreactivity, (a, d, g, and k) 4 hrs after castor oil vehicle injection 
(control), (b, e, h, and l) four hours after 100 mg/kg CQ i.p., (c, f, i, j and m), 24 hours after 
100 mg/kg CQ i.p 
(a-c) temporal hippocampal region, subicular complex, entorhinal and perirhinal cortices, 
scalebars: 500 μm. (d-f) temporal dentate gyrus, arrows mark c-Fos+ cells in the most 
proximal part of the CA3 pyramidal cell layer, gcl: granule cell layer, h: hilus, scalebars: 100 
μm. (g-j) temporal CA1, so: stratum oriens, sr: stratum radiatum, scalebars: 20 μm. (k-m) 
temporal cortex, stars mark layer I, scalebars: 100 μm. 
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Figure 3 
Rat, c-Fos immunoreactivity, mid-septotemporal dentate gyrus, gcl: granule cell layer, h: 
hilus. 
(a) Four hours after castor oil vehicle injection (control), scalebar: 50 μm. (b) four hours after 
200 mg/kg CQ i.p.. CQ-induced c-Fos+ nuclei are typically small and pleiomorphic, whereas 
the number of larger, round neuronal c-Fos+ nuclei does not change visibly. scalebar: 50 μm. 
(c) c-Fos+ cells in the subgranular zone four hours after an i.p. injection of 200 mg/kg CQ, 
scalebar: 25 μm. 
 
Figure 4 
Mouse, CQ-induced histopathological changes, all experimental animals 24 hours after 100 
mg/kg i.p. CQ. 
(a-c) mid-septotemporal dentate gyrus, scalebars: 50 μm. (a) Four hours after castor oil 
vehicle injection (control). (b and c) experimental animals, arrows mark degenerating 
proximal CA3 pyramidal cells. Note the heterogeneous appearance of the granule cell layer in 
b, caused by evenly distributed, darkly staining, degenerating granule cells. In c, only a few 
pale cells of a neuronal phenotype remain in the hilus adjacent to the infrapyramidal blade of 
the granule cell layer. (d and e) hilus of (d) control and (e) experimental animals, arrows mark 
some of the small, dark nuclei that characterize the least affected experimental animals, 
scalebars: 25 μm. (f) CA3-CA1 border, experimental animals (g-h) CA1 of (g) control and (h 
and i) experimental animals, so: stratum oriens, sr: stratum radiatum. scalebars: 25 μm. (j-m) 
medial entorhinal cortex of (j) control and  (k-m) experimental animals, (l) entorhinal cortex 
layer III in an experimental animal in which the entorhinal cortex was affected. scalebars: 
j,k,m -  100 μm, l – 25 μm. 
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Figure 5 
Rat, mid-septotemporal dentate gyrus of (a) a control animal and (b) 48 hours after 100 
mg/kg CQ i.p. In rats, the appearance of this area in control animals is indistinguishable from 
that in experimental animals, whereas the hilus is strongly affected by a similar dose in mice 
(Fig. 4). scalebars: 25 μm 
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TABLES 
 
Table 1 
 Animals used by clioquinol dose and survival time, SD: Sprague Dawley rats, otherwise 
Wistar-Kyoto rats or DBA mice. All animals survived the CQ-dose for the specified survival 
times. 
Rats 
Survival time after i.p.clioquinol clioquinol  
(mg/kg) 3-5 hours 9 hours 16 hours 48 hours 168 hours 
0 9 + 3 SD  1  2 
50 4     
100 11 + 3 SD 3 1 3 5 
200 5  1  2 
Mice      
 3-4 hours 24 hours 
0 8 3 
100 5 10 
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